62 related articles for article (PubMed ID: 15604279)
1. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Arao T; Fukumoto H; Takeda M; Tamura T; Saijo N; Nishio K
Cancer Res; 2004 Dec; 64(24):9101-4. PubMed ID: 15604279
[TBL] [Abstract][Full Text] [Related]
2. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Taguchi F; Koh Y; Koizumi F; Tamura T; Saijo N; Nishio K
Cancer Sci; 2004 Dec; 95(12):984-9. PubMed ID: 15596048
[TBL] [Abstract][Full Text] [Related]
3. ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
Ryan AJ; Wedge SR
Br J Cancer; 2005 Jun; 92 Suppl 1(Suppl 1):S6-13. PubMed ID: 15928657
[TBL] [Abstract][Full Text] [Related]
4. Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.
Yoshikawa D; Ojima H; Kokubu A; Ochiya T; Kasai S; Hirohashi S; Shibata T
Br J Cancer; 2009 Apr; 100(8):1257-66. PubMed ID: 19319137
[TBL] [Abstract][Full Text] [Related]
5. Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer.
Flanigan J; Deshpande H; Gettinger S
Biologics; 2010 Sep; 4():237-43. PubMed ID: 20859451
[TBL] [Abstract][Full Text] [Related]
6. Suppression of Chromosome Instability Limits Acquired Drug Resistance.
Crowley EA; Hermance NM; Herlihy CP; Manning AL
Mol Cancer Ther; 2022 Oct; 21(10):1583-1593. PubMed ID: 35905505
[TBL] [Abstract][Full Text] [Related]
7. Licochalcone A Promotes the Ubiquitination of c-Met to Abrogate Gefitinib Resistance.
Han S; Li X; Gan Y; Li W
Biomed Res Int; 2022; 2022():5687832. PubMed ID: 35309168
[TBL] [Abstract][Full Text] [Related]
8. Experiments from unfinished Registered Reports in the Reproducibility Project: Cancer Biology.
Errington TM; Denis A; Allison AB; Araiza R; Aza-Blanc P; Bower LR; Campos J; Chu H; Denson S; Donham C; Harr K; Haven B; Iorns E; Kwok J; McDonald E; Pelech S; Perfito N; Pike A; Sampey D; Settles M; Scott DA; Sharma V; Tolentino T; Trinh A; Tsui R; Willis B; Wood J; Young L
Elife; 2021 Dec; 10():. PubMed ID: 34874009
[TBL] [Abstract][Full Text] [Related]
9. Nuclear Pyruvate Kinase M2 (PKM2) Contributes to Phosphoserine Aminotransferase 1 (PSAT1)-Mediated Cell Migration in EGFR-Activated Lung Cancer Cells.
Biyik-Sit R; Kruer T; Dougherty S; Bradley JA; Wilkey DW; Merchant ML; Trent JO; Clem BF
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439090
[TBL] [Abstract][Full Text] [Related]
10. Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities.
Coppé JP; Mori M; Pan B; Yau C; Wolf DM; Ruiz-Saenz A; Brunen D; Prahallad A; Cornelissen-Steijger P; Kemper K; Posch C; Wang C; Dreyer CA; Krijgsman O; Lee PRE; Chen Z; Peeper DS; Moasser MM; Bernards R; van 't Veer LJ
Nat Cell Biol; 2019 Jun; 21(6):778-790. PubMed ID: 31160710
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitors.
Ohashi Y; Okamura M; Katayama R; Fang S; Tsutsui S; Akatsuka A; Shan M; Choi HW; Fujita N; Yoshimatsu K; Shiina I; Yamori T; Dan S
Oncotarget; 2018 Jan; 9(2):1641-1655. PubMed ID: 29416720
[TBL] [Abstract][Full Text] [Related]
12. Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors.
Hamamoto J; Yasuda H; Aizawa K; Nishino M; Nukaga S; Hirano T; Kawada I; Naoki K; Betsuyaku T; Soejima K
Oncol Lett; 2017 Sep; 14(3):3559-3565. PubMed ID: 28927112
[TBL] [Abstract][Full Text] [Related]
13. Vandetanib-eluting Radiopaque Beads:
Denys A; Czuczman P; Grey D; Bascal Z; Whomsley R; Kilpatrick H; Lewis AL
Theranostics; 2017; 7(8):2164-2176. PubMed ID: 28740542
[TBL] [Abstract][Full Text] [Related]
14. Effect of
Zhao Y; Liu Y; Lan XM; Xu GL; Sun YZ; Li F; Liu HN
Evid Based Complement Alternat Med; 2016; 2016():1213090. PubMed ID: 28119756
[No Abstract] [Full Text] [Related]
15. Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.
Unni AM; Lockwood WW; Zejnullahu K; Lee-Lin SQ; Varmus H
Elife; 2015 Jun; 4():e06907. PubMed ID: 26047463
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation.
Mashima T; Ushijima M; Matsuura M; Tsukahara S; Kunimasa K; Furuno A; Saito S; Kitamura M; Soma-Nagae T; Seimiya H; Dan S; Yamori T; Tomida A
Cancer Sci; 2015 Jul; 106(7):909-20. PubMed ID: 25911996
[TBL] [Abstract][Full Text] [Related]
17. Potential roles of Centipede Scolopendra extracts as a strategy against EGFR-dependent cancers.
Ma W; Zhang D; Zheng L; Zhan Y; Zhang Y
Am J Transl Res; 2015; 7(1):39-52. PubMed ID: 25755827
[TBL] [Abstract][Full Text] [Related]
18. Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.
Chung BM; Tom E; Zutshi N; Bielecki TA; Band V; Band H
World J Clin Oncol; 2014 Dec; 5(5):806-23. PubMed ID: 25493220
[TBL] [Abstract][Full Text] [Related]
19. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition.
Kogita A; Togashi Y; Hayashi H; Sogabe S; Terashima M; De Velasco MA; Sakai K; Fujita Y; Tomida S; Takeyama Y; Okuno K; Nakagawa K; Nishio K
Int J Oncol; 2014 Oct; 45(4):1430-6. PubMed ID: 25096400
[TBL] [Abstract][Full Text] [Related]
20. Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.
Massarelli E; Onn A; Marom EM; Alden CM; Liu DD; Tran HT; Mino B; Wistuba II; Faiz SA; Bashoura L; Eapen GA; Morice RC; Jack Lee J; Hong WK; Herbst RS; Jimenez CA
Clin Lung Cancer; 2014 Sep; 15(5):379-86. PubMed ID: 24913066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
